The scoreboard, honestly: the hard targets, how often each one is actually looked at,
and the quiet human signals that never make it onto a dashboard.
Major Regulatory Findings & Warning Letters
Number of critical or major findings from health authority inspections (e.g., FDA 483s, EMA Statement of Non-Compliance) and, critically, any Warning Letters.
Target · Zero major findings; zero Warning Letters globally.In Q2, we had two minor FDA 483 observations at our Irish plant, but no critical findings. The target is to keep all sites at zero major observations.
Cost of Non-Compliance (CoNC)
Total financial impact from quality failures, including recalls, scrap, rework, regulatory fines, and legal settlements.
Target · Reduce CoNC by 15% year-on-year; maintain CoNC below 0.2% of total revenue.Last year, CoNC was £8.5M, roughly 0.3% of revenue. This year, we're aiming for £7.2M or less, primarily by reducing batch rejections.
Product Recall Rate & Severity
Number and class (e.g., Class I, II, III) of product recalls initiated due to quality or safety issues.
Target · Zero Class I recalls; maintain Class II/III recalls below 0.01% of batches released.We had one Class II recall in Q1 for a packaging defect in a single market, which was contained swiftly. The goal is to prevent any future recalls, especially those impacting patient safety.
Time to Market for New Products (Compliance-Related Delays)
Delays in new product launches or market expansions specifically attributable to GxP compliance issues or regulatory approval holdups.
Target · Zero compliance-related delays; maintain average regulatory approval timelines within 5% of planned schedule.Our recent oncology drug launch in Germany was delayed by 3 weeks due to an unexpected data integrity query from the EMA. We need to prevent these kinds of delays.
Board & Executive Trust in Compliance Posture
The degree to which the Board and Executive Leadership Team (ELT) view the compliance function as a strategic partner, not just a cost centre or roadblock.
- You'll be proactively sought out for strategic discussions, not just reactive problem-solving. Your input will be critical in M&A due diligence, new market entry, and major investment decisions. The Board will regularly ask for your perspective on emerging regulatory risks and opportunities.
Global Compliance Culture & Awareness
The extent to which compliance principles are embedded in day-to-day operations across all functions and geographies, fostering a 'quality-first' mindset.
- Employees at all levels will demonstrate a clear understanding of GxP requirements and their personal responsibility. You'll see proactive reporting of potential issues, not just reactive fixes. Internal audit findings will show a decreasing trend in systemic compliance gaps, indicating a healthy culture.
Regulatory Foresight & Preparedness
Our ability to anticipate changes in the global regulatory landscape and proactively adapt our systems and processes before new requirements become mandatory.
- We'll be seen as an industry leader in adopting new standards. You'll present clear, actionable strategies to the Board on upcoming regulatory shifts (e.g., new data integrity guidelines, advanced therapy medicinal product regulations). We won't be caught off guard by new health authority expectations.